Early Manufacturability Assessment
De-risk your project early by assessing the manufacturability of your recombinant protein.
Development of Innovative and cutting-edge therapeutics carries the risk of delays or failure if recombinant protein production is insufficient or post-translational modifications are inadequate. At ExcellGene, we help de-risk your project using our fast and comprehensive manufacturability assessment.
Ensure early success in therapeutic projects with
our advanced expertise.
Parallel Testing
Running hundreds of stable pools in parallel to test lead and backup proteins within 5 weeks from transfection to stable fed-batch cultures.
Product Quality
Evaluating protein quality, including post-translational modifications, to meet therapeutic standards.
Productivity Analysis
Assessing production yield to enable estimation of manufacturing costs at large scale (COGS).
Cell Behaviour
Understanding host-cell behaviour under production conditions to predict long-term stability and performance.
Simplicity
Identifying the easiest production pathway to streamline manufacturing processes.
HOW WE CAN HELP
Partnering
with ExcellGene
You gain access to our expertise and advanced technologies, enabling consideration of manufacturability and commercial viability early in the decision-making process, ensuring your therapeutic projects are on the path to success, right from the start.